Why This Isn’t Ready for Clinical Use
The researchers are careful to flag real limitations: cancer stage at diagnosis wasn’t tracked in the database, a meaningful gap, and people who obtained sildenafil outside the formal healthcare system weren’t captured at all. Retrospective health-record analysis, however carefully matched, can’t prove cause and effect the way a randomized clinical trial can. Dr. Erez herself has been direct about the current state of the research, describing the findings as “still far from routine clinical practice” and specifically cautioning against patients seeking out the drug for cancer treatment on their own. The National Cancer Institute, which co-authored the work, echoed that caution, stating plainly that more research is needed before this approach could be shown to safely and effectively prevent metastasis in people. No large randomized trial testing sildenafil specifically for cancer has been completed.
What’s Next
Despite the early stage of the research, the combination of lab, animal, and large-scale patient data gives researchers a reasonable case for pursuing formal clinical trials next. Sildenafil already has decades of safety data behind it from its approved uses, which could make it a faster candidate to formally test as a cancer-supporting therapy than an entirely new drug would be — though until those trials happen, it remains a research finding, not a treatment option.
Source: Ariav, Y., Hayek, S., Cantore, T., et al., including Erez, A. (2026). PDE5a Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking Through a Non-canonical cGMP-Dependent Pathway. Cancer Research. DOI: 10.1158/0008-5472.CAN-26-1818.
For Complete Cooking STEPS Please Head On Over To Next Page Or Open button (>) and don’t forget to SHARE with your Facebook friends.
